Immunoconjugate | List of Frontiers open access articles

Case Report

Published on 02 Oct 2020

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report

in Hematologic Malignancies

Dennis Christoph Harrer
Karin Menhart
Stephanie Mayer
Wolfgang Herr
Albrecht Reichle
Martin Vogelhuber

Frontiers in Oncology

doi 10.3389/fonc.2020.585830

6,979 views
1 citation

Original Research

Published on 21 Aug 2019

Sensitization of Tumors for Attack by Virus-Specific CD8+ T-Cells Through Antibody-Mediated Delivery of Immunogenic T-Cell Epitopes

in Cancer Immunity and Immunotherapy

Julian P. Sefrin
Lars Hillringhaus
Olaf Mundigl
Karin Mann
Doris Ziegler-Landesberger
Heike Seul
Gloria Tabares
Dominic Knoblauch
Andreas Leinenbach
Irene Friligou

Frontiers in Immunology

doi 10.3389/fimmu.2019.01962

9,290 views
26 citations

Original Research

Published on 18 Feb 2019

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53

in Hematologic Malignancies

Elena Tirrò
Michele Massimino
Chiara Romano
Maria Stella Pennisi
Stefania Stella
Silvia Rita Vitale
Annamaria Fidilio
Livia Manzella
Nunziatina Laura Parrinello
Fabio Stagno

Frontiers in Oncology

doi 10.3389/fonc.2019.00057

6,148 views
30 citations

Review

Published on 31 Mar 2015

A pretargeting system for tumor PET imaging and radioimmunotherapy

in Experimental Pharmacology and Drug Discovery

Françoise Kraeber-Bodéré
Caroline Rousseau
Caroline Bodet-Milin
Eric Frampas
Alain Faivre-Chauvet
Aurore Rauscher
Robert M. Sharkey
David M. Goldenberg
Jean-François Chatal
Jacques Barbet

Frontiers in Pharmacology

doi 10.3389/fphar.2015.00054

10,585 views
50 citations

Original Research

Published on 24 May 2021

Intramuscular Expression of Plasmid-Encoded FVII-Fc Immunoconjugate for Tumor Immunotherapy by Targeting Tumoral Blood Vessels and Cells

in Cancer Immunity and Immunotherapy

Liping Ma
Guanru Wang
Sijia Liu
Feng Bi
Ming Liu
Gang Wang

Frontiers in Oncology

doi 10.3389/fonc.2021.638591

2,903 views
4 citations

Original Research

Published on 21 Aug 2017

Development and Characterization of a Camelid Single Domain Antibody–Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2

in Vaccines and Molecular Therapeutics

Baomin Tian
Wah Yau Wong
Marni D. Uger
Pawel Wisniewski
Heman Chao

Frontiers in Immunology

doi 10.3389/fimmu.2017.00956

7,962 views
16 citations

Articles

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report

Sensitization of Tumors for Attack by Virus-Specific CD8+ T-Cells Through Antibody-Mediated Delivery of Immunogenic T-Cell Epitopes

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53

A pretargeting system for tumor PET imaging and radioimmunotherapy

Intramuscular Expression of Plasmid-Encoded FVII-Fc Immunoconjugate for Tumor Immunotherapy by Targeting Tumoral Blood Vessels and Cells

Development and Characterization of a Camelid Single Domain Antibody–Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2